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ABSTRACT: The progressive accumulation of amyloid-beta
(Aβ) in specific areas of the brain is a common prelude to late-
onset of Alzheimer’s disease (AD). Although activation of liver
X receptors (LXR) with agonists decreases Aβ levels and
ameliorates contextual memory deficit, concomitant hyper-
cholesterolemia/hypertriglyceridemia limits their clinical appli-
cation. DMHCA (N,N-dimethyl-3β-hydroxycholenamide) is an
LXR partial agonist that, despite inducing the expression of
apolipoprotein E (main responsible of Aβ drainage from the
brain) without increasing cholesterol/triglyceride levels, shows nil activity in vivo because of a low solubility and inability to
cross the blood brain barrier. Herein, we describe a polymer therapeutic for the delivery of DMHCA. The covalent
incorporation of DMHCA into a PEG-dendritic scaffold via carboxylate esters produces an amphiphilic copolymer that
efficiently self-assembles into nanometric micelles that exert a biological effect in primary cultures of the central nervous
system (CNS) and experimental animals using the intranasal route. After CNS biodistribution and effective doses of DMHCA
micelles were determined in nontransgenic mice, a transgenic AD-like mouse model of cerebral amyloidosis was treated with
the micelles for 21 days. The benefits of the treatment included prevention of memory deterioration and a significant
reduction of hippocampal Aβ oligomers without affecting plasma lipid levels. These results represent a proof of principle for
further clinical developments of DMHCA delivery systems.
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The progressive accumulation of amyloid-beta (Aβ) inspecific areas of the brain is a common prelude to late-onset of Alzheimer’s disease (AD).1 The amyloid-
cascade hypothesis has been for more than 25 years the central
dogma for the development of AD.2,3 This hypothesis states
than imbalance between the production and clearance of Aβ in
the brain of affected individuals is responsible for neuro-
degeneration and dementia. Monomeric Aβ progressively
aggregates into Aβ oligomers and finally into amyloid fibrils,
found in AD plaques previously considered to be the cause of
cognitive deficits. Since the amounts of Aβ fibrillar plaques do
not correlate with cognitive decline,4,5 researchers have
focused on the study of both soluble and membrane-associated
Aβ oligomers to identify the Aβ form responsible for
neurotoxicity. In this regard, strong evidence suggests that
instead of monomer or Aβ fibrils, diffusible Aβ oligomers are
largely suspected to be responsible for development and
progression of cognitive deterioration characteristic of AD,
causing direct injury to neurons, enhancing neuroinflamma-
tion, astrocytosis, gliosis, and eventually neuronal loss.2,6,7 As a
result, the age-related impairment of Aβ homeostatic
mechanisms has been postulated as a critical determinant of
disease risk with even modest reductions in clearance of
soluble Aβ resulting in elevated levels of Aβ oligomers and
ultimately their progressive and chronic deposition within the
brain. This process occurs while individuals are still cognitively
normal. Thus, early intervention aimed to eliminating toxic Aβ
oligomers in the brain offer a promising preventive therapeutic
strategy not only to halt the development and progression of
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AD but also as a promising target for causal treatment of the
disease.
The main contribution to Aβ drainage from the brain comes
from apolipoprotein E (ApoE),8,9 the strongest genetic risk
factor of AD,10 which modulates Aβ removal to the systemic
circulation by its transport across the blood brain barrier
(BBB).11,12 The interaction between ApoE and Aβ is
conditioned by the correct lipidation of ApoE, which is
induced by the ATP-binding cassette transporter A1
(ABCA1).13,14 When amyloid precursor protein (APP) Tg
mice are crossed onto an ABCA1−/− background, decreased
ApoE lipidation and increased amyloid deposition are
observed,13,15,16 whereas increasing ABCA1 favors ApoE
lipidation and reduces amyloid deposition.14 Both ApoE and
ABCA1 are modulated by cerebral expression of liver X
receptors (LXRs) and mainly produced in the central nervous
system (CNS) by astrocytes.17
Several studies have explored the potential utility of LXRs
agonists in AD therapy.13,14,17,18 In vivo studies using AD-like
transgenic mouse models have revealed that LXRs agonists
provoke an upregulation of ApoE and ABCA1 expression, a
marked reduction in Aβ levels, enhanced brain cholesterol
turnover, and reversed contextual memory deficits.19−21
However, a major concern with LXRs agonists is that they
not only drive up transcription of ApoE and ABCA1 but also
upregulate genes associated with fatty acid synthesis. As a
result, the therapeutic application of LXRs agonists has been
restricted due to undesirable side effects, promoting lipo-
genesis and triglyceride accretion through the activation of
sterol-response element binding protein 1c (SREBP-1c)
expression.22
DMHCA (N,N-dimethyl-3β-hydroxycholenamide, Figure 1)
is a gene-selective LXR modulator that mediates potent
transcriptional activation of ABCA1 and ApoE gene
expression, while minimally affecting SREBP-1c.22,23 Thus, it
represents an excellent therapeutic candidate for AD, circum-
venting the side effects of alternative LXRs agonists. Still,
DMHCA’s very low solubility and inability to cross the BBB
limits its application in vivo.24 To overcome these short-
comings and achieve enough delivery to target areas of the
brain, herein we describe the covalent incorporation of
DMHCA into a micellar polymer therapeutic, exploiting its
unique hydroxyl group as chemical handle. Functionalization
of a PEG-dendritic scaffold25 [PEG is poly(ethylene glycol), a
linear, hydrophilic polymer, characterized by low toxicity and
immunogenicity and widely used for biomedical applica-
tions]26 with DMHCA has afforded an amphiphilic copolymer
with precise stoichiometry that efficiently self-assembles into
nanometric micelles (Figure 1) for intranasal administration.
RESULTS AND DISCUSSION
Figure 1 shows PEG-[G1]-DMHCA, a conjugate incorporating
a PEG5k chain, a GATG (gallic acid-triethylene glycol)
27−29
dendritic block of first generation, and three pendant DMHCA
molecules connected via carboxylate esters. These linkages
were selected because of their known biodegradability in vivo
by pH and the action of esterases and thus frequent use in the
design of prodrugs.30−32 In addition, esters show a good
compromise between biodegradability and synthetic manipu-
lation. GATG dendrimers have been developed in our
laboratory as a platform for biomedical applications.27−29
They are composed of a repeating unit incorporating a gallic
acid core and hydrophilic triethylene glycol arms carrying
terminal azides.33
The synthetic strategy toward PEG-[G1]-DMHCA has
relied on an initial esterification of DMHCA with 4-pentynoic
acid to afford DMHCA-Alk (EDC, DMAP, 90%), an alkynated
derivative that was then connected via Cu(I)-catalyzed azide−
alkyne cycloaddition (CuAAC)34 to PEG-[G1]-N3, a dendritic
copolymer carrying three terminal azides, available in gram
quantities in just one step35 (Figure 1). A proper selection of
the reaction conditions and the presence of catalytic
tris(benzyltriazolylmethyl) amine (TBTA) were determining
factors to efficiently lead CuAAC to completion [CuSO4,
ascorbate, TBTA, THF/H2O (4:1), 60 °C; see Table S1).
PEG-[G1]-DMHCA was obtained in very good yield (81%)
and chemically characterized with convincing evidence by 1H
NMR (disappearance of the methylene protons adjacent to the
azide at 3.40 ppm, appearance of new triazol protons at 7.51
ppm), 13C NMR (new triazol at 122.2 and 127.9 ppm), IR
spectroscopy (loss of the intense azide band at 2100 cm−1),
and MALDI-TOF MS (a series of 44 Da spaced peaks with Mp
and Mw in agreement with expected values) as described in
Supporting Information (SI). In addition, characteristic new
signals in the 1H NMR [5.35 (alkene) and 3.00−2.93 ppm
(N,N-dimethylamide)] and 13C NMR spectra [173.6 ppm
(amide) and 139.5 ppm (alkene)] confirmed the incorporation
of DMHCA.
Micellar assembles of PEG-[G1]-DMHCA were obtained by
an evaporation method in acetone/H2O (1:1). Dynamic light
scattering (DLS) measurements confirmed a mean diameter of
about 22 ± 1 nm in agreement with transmission electron
Figure 1. Synthesis of PEG-[G1]-DMHCA (A). Preparation of micelles (B). DLS histogram (C) and TEM image (D) of micelles.
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microscopy (TEM) images (Figures 1 and S2). These micelles
containing a high 20% DMHCA drug loading were stable in
solution for at least 1 week without variation in size or ester
hydrolysis being observed (Figure S6). They could be freeze-
dried and successfully resuspended in PBS (Figure S3), both
relevant properties for storage and handling. Finally, to
proceed with an in vitro/in vivo evaluation, a biotinylated
version of the micelles was obtained from Biotin-PEG-[G1]-
DMHCA, a copolymer carrying biotin at the distal end of the
PEG block prepared following a similar strategy from BocHN-
PEG-[G1]-N3 (a copolymer analogous to PEG-[G1]-N3 that
incorporates a terminal protected amino group)36 (Scheme S1
and Figure S4).
To determine the therapeutic efficacy of PEG-[G1]-
DMHCA, we compared the effect of DMHCA versus PEG-
[G1]-DMHCA micelles on the ABCA1 and ApoE cell
expression (PEG-[G1]-CO2H, the block copolymer resulting
after hydrolysis of DMCHA was used as control). After 14 days
in vitro, rat cortical neuronal and glial cocultured cells (800 000
cells per well) were treated for 24 h with 10 μM free or
micellar DMHCA. Levels of ABCA1 and ApoE were resolved
by Western blots (Figure 2A). As depicted in Figure 2B, there
Figure 2. Biological effect of free DMHCA versus PEG-[G1]-DMHCA micelles versus PEG-[G1]-CO2H (control) over ABCA1 and ApoE
levels tested on cerebral cortical cocultures treated for 24 h (A,B). Statics analysis were performed using GraphPad Prism 6. All probability
values were two-tailed; a level of 5% was considered significant. Data are reported as the mean ± SEM. Confocal microscopy (C) of
displaying neuronal (panel II; βIII-tubulin, green) and astrocytes (panel IV; GFAP, green) binding Biotin-PEG-[G1]-DMHCA (red)
compared with controls (panels I and III, respectively). Nuclei stained in blue (DAPI). Scale bar, 10 μm.
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were statistically significant increases in both target proteins in
free DMHCA treated cells versus control (t test p ≤ 0.01**
and p ≤ 0.05*, respectively) and DMHCA micelles treated
cells versus control (t test p ≤ 0.01** for both markers). The
Figure 3. Biotin-PEG-[G1]-DMHCA intranasally administered reaches the hippocampus after 24 h. In the images, the colocalization of the
used markers (red for GFAP/blue for DAPI, nuclei/green for Biotin) can be observed at 20× and 40× (scale bars 50 and 25 μm,
respectively) (A,B). Effective intranasal dose analysis in mice: olfactory bulb levels of ApoE evaluated after 24 h by Western Blot (C).
Relative levels of ApoE in homogenates of hippocampus, cerebral cortex, and liver; normalizing with values of βIII-tubulin for hippocampus
and cerebral cortex, and GAPDH for liver (D,E). Statics analysis was performed using Graph-Pad Prism 6. All probability values were two-
tailed; a level of 5% was considered significant. Data are reported as the mean ± SEM.
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most striking finding is that both DMHCA and PEG-[G1]-
DMHCA micelles upregulated target protein expression with
respect to control with no statistical differences between them,
confirming that PEG-[G1]-DMHCA micelles exert in vitro
selective biological effects on ABCA1 and ApoE through LXRs
activation.
Then, the target specificity of PEG-[G1]-DMHCA was
evaluated by confocal imaging using the biotinylated version of
the micelles. Neurons and astrocytes were incubated with
Biotin-PEG-[G1]-DMHCA micelles (10 μM DMHCA) for 2
h. The distribution of Biotin-PEG-[G1]-DMHCA was
examined, staining biotin with streptavidin-Alexa Fluor 594
Figure 4. (A) Novel object recognition test: memory retention was tested 24 h after training. Data are mean ± SEM exploratory preferences
during training (left columns) or test (white and gray columns; F, familiar; N, novel) trials (n = 8 per group). (B) Immunoreactive Aβ
burden in the cerebral cortex (CCx) and hippocampus (Hipp) of PEG-[G1]-CO2H versus PEG-[G1]-DMHCA treated mice. (C) Positive
immunoreactive neurons were quantified using the Image Pro Plus software. (D) Hippocampal homogenates were resolved by Western blots
using the 6E10 antibody; a particular reduction of the 12 kDa band, referred as Aβ trimers (p ≤ 0.05,*, independent t test) was observed (E).
Lipid plasma profile shows not statistically significant differences (independent t test) in the levels of cholesterol (F) and triglycerides (G)
among groups. Statics analysis were performed using Graph-Pad Prism 6. All probability values were two-tailed; a level of 5% was considered
significant. Data are reported as the mean ± SEM.
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(red) and nuclei with DAPI (blue). Neurons were marked with
an anti-βIII-tubulin and a secondary antibody labeled with
Alexa Fluor 488 (green). Biotin-PEG-[G1]-DMHCA displayed
a strong signal and colocalized with neurons compared with
control cells (Figure 2C, panels I and II). Similarly, astrocytes
labeled with anti-GFAP (glial fibrillary acidic protein) and a
secondary antibody-Alexa Fluor 488 (green) overlapped with
Biotin-PEG-[G1]-DMHCA (red) (Figure 2C, panel III and
control in panel IV). Overall, confocal imaging for primary cell
culture displayed fluorescence intensity for both, neurons and
astrocytes.
Having demonstrated the colocalization of PEG-[G1]-
DMHCA with cells of the CNS in vitro, the in vivo
administration of micelles was evaluated in mice. Drug delivery
to the brain for the treatment of a wide variety of diseases has
been traditionally hampered by the BBB. In recent years, the
intranasal administration has come to light as an effective nose-
to-brain passage that circumvents the BBB. The olfactory
epithelium provides a direct pathway for the noninvasive,
rapid, and comfortable delivery of therapeutic agents and drug
delivery systems, including dendrimer nanoplatforms, to the
CNS.37−39 Administration doses of 0.2, 5, and 10 mg
DMHCA/kg body weight/day (equivalent to 1, 25, and 50
mg of DMHCA micelles/kg body weight/day) were tested by
intranasal administration. Mice received 5 μL per nostril of a
solution of Biotin-PEG-[G1]-DMHCA micelles and after 4,
12, and 24 h of administration, cerebral cortex and hippo-
campus were analyzed (Figure 3). At 24 h post intranasal
administration, confocal images (20×) delivered an overlapped
green signal from Biotin-PEG-[G1]-DMHCA (stained with
streptavidin-Alexa Fluor 488) and an astrocytes red signal from
GFAP (marked with anti-GFAP followed by a secondary
antibody-Alexa Fluor 594) in treated mice versus controls both
at 5 and 10 mg of DMHCA/kg body weight/day (Figure
3A,B). At higher magnification (40×), in some images of the
hippocampus, Biotin-PEG-[G1]-DMHCA also overlapped
with DAPI (blue), indicating accumulation in the nuclei,
where LXRs are expressed (Figure 3B).
In previously reported studies of DMHCA, experimental
doses in mice ranged from 8 to 80 mg/kg body weight/day for
systemic or oral administration, without penetration through
the BBB.22,23,40 We explored a range of four different doses of
DMHCA, 0.3, 1.5, 3, and 15 mg/kg body weight/day,
equivalent to 1.5, 7.5, 15, and 75 mg of PEG-[G1]-
DMHCA/kg body weight/day. Animals were divided in five
groups (n = 4 per group) and received a single intranasal dose
with increasing concentrations of DMHCA micelles (10 μL
total volume, 5 μL/nostril). After 24 h, mice were deeply
anaesthetized and brains were rapidly removed. As depicted in
Figure 3C, olfactory bulb levels of ApoE resolved by Western
blots revealed that mice receiving 3 mg of DMHCA displayed
increased relative ApoE levels compared to controls (p ≤
0.001, ***) and the 0.3 mg (p ≤ 0.001, ***) and 1.5 mg (p ≤
0.01, **) groups. However, no significant differences were
observed between the 3 and 15 mg groups. Altogether, we
concluded that 3 mg of DMHCA/kg body weight/day
displayed an effective dose−response, triggering upregulation
of ApoE levels. As expected, the intranasal treatment of free
DMHCA at the same concentrations did not affect the levels of
ApoE.
To check the effectiveness of the selected pharmacological
dose of DMHCA micelles (3 mg DMHCA/kg body weight/
day) at different times post intranasal administration,
experimental mice were divided into six groups (n = 5 per
group), as follows: group A (control), saline; group B, one
dose administered at time 0 and sacrificed 4 h later; group C,
one dose at time 0 and sacrificed after 12 h, group D, one dose
at time 0 and sacrificed after 24 h; group E, two doses at time 0
and 24 h, sacrificed at 48 h post first administration; and group
F, three doses at time 0, 24, and 48 h, sacrificed at 72 h post
first administration. As shown in Figure 3D, relative ApoE
levels were determined by Western blots in hippocampus,
cerebral cortex, and liver. Quantification in Figure 3E shows a
significant increase in ApoE levels at 48 h post initial
administration in hippocampus and cerebral cortex. An
increase in ApoE levels (p ≤ 0.05,*) at 24 h post initiation
of administration is also observed in liver likely due to the high
LXRs hepatic expression.
Next, we investigated the potential in vivo pharmacological
effects of PEG-[G1]-DMHCA micelles on associated memory
impairment and Aβ burden in our well-characterized AD-like
amyloid pathology transgenic (Tg) mice.41 Three month old
mice were divided into two groups. A control group received
daily 10 μL (5 μL/nostril) intranasal administration of PEG-
[G1]-CO2H (copolymer lacking DMHCA; 15 mg/kg body
weight/day) for 21 consecutive days. The experimental group
followed the same protocol and received 15 mg/kg body
weight/day of DMHCA micelles (equivalent to 3 mg
DMHCA/kg body weight/day). At the end of the treatment,
we investigated whether chronic intranasal treatment with
PEG-[G1]-DMHCA could prevent object recognition memory
deficits characteristic of our Tg mice at this age [novel object
recognition test (NOR)]. Gratifyingly, PEG-[G1]-DMHCA
treated mice performed significantly better on the object
recognition task than control mice (p < 0.05,*) and similar to
nontransgenic age-matched littermates (Figure 4A). Figure 4B
illustrates the immunoreactive Aβ burden in the right cerebral
cortex and hippocampus of PEG-[G1]-CO2H versus PEG-
[G1]-DMHCA treated mice. The study revealed a significant
reduction (p ≤ 0.05,*) of Aβ positive neurons following PEG-
[G1]-DMHCA treatment compared to control (Figure 4C).
Left hippocampal homogenates were resolved by Western
blots using the 6E10 antibody (Figure 4D). The analysis
revealed several immunoreactive bands in Tg/PEG-[G1]-
CO2H animals between 12 and 120 kDa, mainly oligomeric
forms of Aβ not appearing in hippocampal Tg/PEG-[G1]-
DMHCA homogenates. Clearly, the micellar DMHCA treat-
ment results in the clearance of most of the hippocampal 6E10
immunoreactive bands with a particular reduction of the 12
kDa band, referred to as Aβ trimers (p ≤ 0.05,*; Figure 4E).
Lastly, considering that significant efforts are currently directed
toward developing LXRs ligands that lack an undesired
upregulation of hepatic lipogenesis, the lipid plasma profile
was studied, revealing no statistically significant differences in
the plasma levels of cholesterol and triglycerides among groups
(Figure 4F,G).
Finally, the potential cytotoxicity of the intranasal treatment
with DMHCA micelles was evaluated in mice using a caspase
3/7 assay. Apoptosis is the process of programmed cell death
that occurs in all living organisms. Detecting apoptosis is key to
determine mechanisms of cell toxicity. In mammalian cells,
apoptosis is accompanied by an increased production of
caspases, enzymes responsible for the activation of signaling
pathways and the proteolytic dismantling of key processes
ultimately leading to cell death. To study the potential
cytotoxic effects in vivo of PEG-[G1]-DMHCA micelles, we
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have investigated the specific activation of two effector
caspases, caspase-3 and 7, which are downstream of the
initiator events of the apoptotic cascade (see the SI). The
analysis of homogenates of the olfactory bulb, hippocampus,
cerebral cortex and liver of mice treated with PEG-[G1]-
DMHCA micelles at different time-points (up to 72 h)
indicates that the treatment does not mediate in vivo cell
toxicity through an apoptotic mechanism at any of the
experimental doses (Figure S7). The cytotoxic effect of the
long-term PEG-[G1]-DMHCA treatment was also studied in
21 days-treated transgenic mice (Figure S8). Our studies do
not reveal any statistical differences in caspase 3/7 activity
between tissues [brain (olfactory bulb, hippocampus, and
cerebral cortex), liver, lungs, and heart] of non Tg and Tg mice
treated with PEG-[G1]-CO2H (control) or PEG-[G1]-
DMHCA micelles. Overall, our results indicate that the long-
term intranasal treatment of PEG-[G1]-DMHCA micelles at
the experimental dose (3 mg/kg body weight/day) does not
trigger caspase-related cell toxicity mechanisms in our mice
model.
CONCLUSIONS
The age-related impairment of Aβ homeostatic mechanisms
has been postulated as a critical determinant of disease risk in
AD with even modest reductions in the clearance of soluble Aβ
resulting in elevated levels of toxic oligomers, and ultimately
their progressive and chronic deposition within the brain.
DMHCA represents an LXR partial agonist that despite
inducing the expression of ApoE (mainly responsible of Aβ
drainage from the brain) shows nil activity in vivo because of
low solubility/inability to cross the BBB. Our DMHCA
polymer therapeutic approach of intranasally administered
dendritic micelles at very early stages of the pathology
effectively prevents cognitive deficits assessed by the NOR
test and reduces Aβ deposition without undesirable side
effects, leaving the plasma levels of cholesterol and triglycerides
unaffected. We believe these studies render suitable proof of
principle for further successful clinical applications of DMHCA
delivery systems.
EXPERIMENTAL SECTION
Synthesis of DMHCA-Alk. DMHCA (100 mg, 0.25 mmol),
DMAP (6.1 mg, 49.8 μmol), and EDC·HCl (62 mg, 0.32 mmol) were
added to a solution of 4-pentynoic acid (29 mg, 0.30 mmol) in
CH2Cl2 (0.5 mL) under Ar. After 20 h of stirring at room
temperature, the solvent was evaporated and the mixture was diluted
with CH2Cl2 (15 mL) and washed with 0.5 M HCl (2 × 10 mL) and
brine (15 mL). The organic layer was dried (MgSO4) and
concentrated to give a crude product that was purified by automated
MPLC (gradient from hexane to EtOAc, silica, 15 min) to afford
DMHCA-Alk (109 mg, 90%) as a white crystalline solid. 1H NMR
(400 MHz, CDCl3) δ: 5.37 (d, J = 4.6 Hz, 1H), 4.71−4.56 (m, 1H),
3.00 (s, 3H), 2.93 (s, 3H), 2.57−2.44 (m, 4H), 2.41−2.14 (m, 4H),
2.05−0.88 (m, 28H), 0.68 (s, 3H). 13C NMR (100 MHz, CDCl3) δ:
173.8, 171.3, 139.7, 122.8, 82.7, 74.5, 69.1, 56.8, 56.0, 50.1, 42.5, 39.8,
38.2, 37.5, 37.1, 36.7, 35.7, 35.5, 33.8, 32.0, 31.4, 30.5, 28.3, 27.9,
24.4, 21.2, 19.4, 18.7, 14.6, 12.0. IR (ATR): 3321, 2933, 2851, 1733,
1625 cm−1. ESI-MS (m/z): 482.3632. Calcd for [M + H]+,
C31H47NO3: 482.3634.
Synthesis of PEG-[G1]-DMHCA. DMHCA-Alk (49 mg, 0.10
mmol) was added to a solution of PEG-[G1]-N3 (100 mg, 17 μmol)
in a mixture of THF (0.41 mL) and H2O (26 μL). Then, TBTA (2.7
mg, 5.10 μmol), CuSO4 (12.8 μL, 2.55 μmol, 0.2 M, 5 mol % per
azide), and sodium ascorbate (64.0 μL, 12.80 μmol, 0.2 M, 25 mol %
per azide) were added. After 12 h of stirring at 60 °C, a second
portion of sodium ascorbate (64.0 μL, 12.80 μmol, 0.2 M, 25 mol %
per azide) was added. After additional 24 h of stirring at 60 °C, the
reaction mixture was partitioned between CH2Cl2 (15 mL) and 0.1 M
EDTA pH 7 (15 mL). The organic layer was washed again with 0.1 M
EDTA pH 7 (2 × 15 mL) and brine (15 mL). Then, it was dried
(MgSO4), evaporated, and purified by precipitation (CH2Cl2/Et2O)
to afford PEG-[G1]-DMHCA (100 mg, 81%) as a white solid. 1H
NMR (750 MHz, CDCl3) δ: 7.51 (s, 3H), 7.09 (s, 2H), 5.35 (d, J =
5.1 Hz, 3H), 4.63−4.54 (m, 3H), 4.52−4.42 (m, 6H), 4.26−4.07 (m,
8H), 3.90−3.50 (m, ∼484H), 3.40−3.31 (m, 7H), 3.04−2.96 (m,
15H), 2.93 (s, 9H), 2.72−2.64 (m, 6H), 2.35 (ddd, J = 15.6, 11.0, 5.1
Hz, 3H), 2.28 (d, J = 8.2 Hz, 6H), 2.20 (ddd, J = 14.8, 10.7, 5.6 Hz,
3H), 2.02−1.92 (m, 6H), 1.91−1.75 (m, 12H), 1.61−1.40 (m, 20H),
1.36−0.90 (m, 43H), 0.67 (s, 9H). 13C NMR (100 MHz, CDCl3) δ:
173.6, 172.1, 166.9, 156.4, 152.3, 146.2, 139.5, 129.0, 127.9, 122.6,
122.2, 107.0, 74.1, 72.3, 71.9, 70.8, 70.2, 69.5, 68.8, 63.9, 59.0, 56.6,
55.9, 50.1, 49.9, 42.3, 39.6, 38.0, 37.3, 36.9, 36.5, 35.6, 35.4, 34.0,
31.8, 31.2, 30.3, 28.1, 27.7, 24.2, 21.0, 19.3, 18.5, 11.8. IR (ATR):
3523, 2868, 1730, 1640, 1104 cm−1. MALDI-TOF MS (HABA, linear
mode, m/z): Calcd, Mp 7251 ([M + H]
+), Mn 7278; Found, Mp 7258
([M + H]+), Mn 7243, Mw 7272.
Preparation of DMHCA Micelles. PEG-[G1]-DMHCA was
dissolved in a mixture of acetone/H2O (1:1, 0.5 mg/mL) and stirred
at room temperature for 48 h until acetone was completely
evaporated. The resulting micelles (1 mg/mL) were freeze-dried.
Biotin-PEG-[G1]-DMHCA micelles with a 10% biotin loading were
prepared following the same procedure as above from a mixture of
PEG-[G1]-DMHCA and Biotin-PEG-[G1]-DMHCA in a molar ratio
9:1. DLS histograms and correlation functions of the micelles as
prepared and after resuspension in 10 mM PB, pH 7.4, 150 mM NaCl
(1 mg/mL) are shown in Figure S2−S4.
1H NMR analysis of the micelles revealed at a glance that there is a
core−corona structure (Figure S5). Only resonances for the flexible
PEG chains at the hydrophilic corona are visible, whereas nuclei from
DMHCA and the dendritic block are absent from the spectrum as a
result of their restricted mobility at the compact core. Interestingly, no
ester hydrolysis is observed during the preparation/storage of the
micelles as revealed by the 1H NMR of a lyophilized sample of
micelles after being redissolved in CDCl3 (Figure S6).
Primary Neuronal/Glial Cultures. Primary cortical cells
(neurons cocultured with glia) were obtained from embryonic rats
using a standard procedure. Briefly, 8−10 embryos E15−16 were
extracted from the uterus of pregnant Wistar rats and cerebral cortices
were isolated in HBSS buffer (Thermo Scientific). The tissue was
incubated with 2 mL of 0.25% trypsin-EDTA (Thermo Scientific) for
15 min at 37 °C and then washed twice with DMEM/F12−10% FBS.
The medium was replaced by Neurobasal (Thermo Scientific) and
cortices were homogenized by pipetting up and down. After that, cells
were incubated for 10 min at room temperature and then centrifuged
at 200×g for 5 min. The medium was discarded and replaced with 2
mL of neuronal medium (Neurobasal, 2 mM L-glutamine, 2% B27
(Thermo Scientific), 100 U/mL penicillin, 100 μg/mL streptomycin).
Cells were resuspended, and viability was assessed with Trypan blue
dye. Then, cells were plated in previously poly-L-lysine coated 12 mm-
diameter coverslips for immunofluorescence experiments (150 000
cells per coverslip) or 6-multiwell plates for Western blot experiments
(800 000 cells per well) and maintained in a 37 °C humidified
incubator with 5% CO2 until DIV (days in vitro) 14.
In Vitro Biological Effects. The primary cell culture was plated at
800 000 cells per well in 6-well plates. Immediately, PEG-[G1]-CO2H
(control), free DMHCA, or PEG-[G1]-DMHCA micelles were added
to the conditioned medium of DIV14 cells to a final concentration of
10 μM DMHCA. Cultures were then incubated in a 37 °C humidified
incubator with 5% CO2 for 24 h. After incubation, the conditioned
medium was aspirated and cells (neurons and glia) were washed in
cold PBS and lysed in RIPA buffer containing protease inhibitors
(SigmaFast protease inhibitor, St. Louis, MO).
Cell Uptake Experiment and Fluorescence Imaging In Vitro.
Biotin-PEG-[G1]-DMHCA micelles were added to the conditioned
medium of DIV14 cells to a final concentration of 10 μM of DMHCA,
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and cultures were then incubated in a 37 °C humidified incubator
with 5% CO2 for 2 h. Then, the conditioned medium was aspirated,
and cultures were washed with cold PBS and fixed in 4% PFA. Cells
were incubated with primary antibodies anti-βIII-tubulin (1:1000,
mouse, Promega) or antiglial fibrillary acidic protein (GFAP 1:1000,
rabbit, Dako) overnight at 4 °C, followed by incubation with
secondary antibodies labeled with Alexa Fluor 488 (green) or
streptavidin-Alexa Fluor 594 (red). Coverslips were mounted with
Mounting Medium with DAPI (blue) and images were obtained with
a confocal Zeiss LSM 510 Meta microscope with a 40× oil-immersion
lens and analyzed with LSM5 image browser software.
Confocal Fluorescence Imaging. Mice received a single
intranasal dose of Biotin-PEG-[G1]-DMHCA micelles (0.6 mg in
10 μL PBS), and 24 h later their brains were perfused-fixed. Then, 30
μm thick sections containing the hippocampus and cerebral cortex
regions were prepared, and double immunostaining was performed to
identify astrocytes and Biotin-PEG-[G1]-DMHCA. DAPI was added
to stain nuclei (blue). Astrocytes were identified with rabbit antiglial
fibrillary acidic protein (GFAP 1:1000, rabbit, Dako) followed by
incubation with secondary antibodies labeled with Alexa Fluor 594
(red). Biotin-PEG-[G1]-DMHCA was identified using streptavidin-
Alexa Fluor 488 (green). In all cases, sections were preincubated,
blocked with the corresponding normal serum secondary antibody
and coverslips were mounted with Gelvatol. The colocalization of
Biotin-PEG-[G1]-DMHCA and astrocytes marker images were
obtained with a confocal Zeiss LSM 510 Meta microscope with a
40× oil-immersion lens and analyzed with LSM5 image browser
software.
Animals, Intranasal Delivery Dose−Response, and Treat-
ment Experiments. Three-month-old mice (n = 4−5/condition)
were weighed and assigned to treatment groups. Mice received daily
intranasal delivery of control (PEG-[G1]-CO2H or saline) or PEG-
[G1]-DMHCA micelles in PBS. The intranasal delivery was
performed according to the protocol described by Hanson et al.42
First, mice were subjected to simulated delivery for 1 week before
treatments to reduce the stress due to the procedure.
For intranasal delivery, mice were hand-restrained, placed in a
supine position, and given two 5 μL drops of PEG-[G1]-DMHCA
micelles, or a control solution, into both nostrils consecutively. Mice
were given an extra 5 μL treatment drop if the subject forcibly ejected
or sneezed out the solution. Mice were held supine for 5−10 s after
delivery to ensure that all fluid was inhaled. These volumes have
shown to deliver drugs mostly to the brain without passage to the
pulmonary regions. For dose−response experiments, mice received a
range of 0.01 to 0.5 mg DMHCA per animal contained into micelles
(equivalent to 0.3−15 mg DMHCA/kg body weight/day).
For treatment experiments, McGill-Thy1-APP transgenic (Tg)
mice were three months old when they started the treatment and were
sacrificed 21 days after. Young, preplaque three month old Tg mice
received 15 mg/kg body weight/day of PEG-[G1]-CO2H (Tg-
control) or 15 mg/kg body weight/day of PEG-[G1]-DMHCA
micelles by intranasal administration for a 3 week period (non Tg
control, n = 5 received intranasal administration of PBS; Tg/PEG-
[G1]-CO2H, n = 5; Tg/PEG-[G1]-DMHCA micelles, n = 5). The
animals were housed in groups of up to four in individually ventilated
cages under standard conditions (22 °C, 12 h light−dark cycle)
receiving food and water ad libitum. All procedures were approved by
the Animal Care Committee of the Catholic University of Cuyo,
Argentine and followed the guidelines of the Argentinean Council on
Animal Care.
Perfusion and Tissue Preparation Technique. Experimental
mice were deeply anesthetized with equithesin (pentobarbital-based,
2.5 mL/kg, i.p.) and perfused through the heart with ice-cold saline
solution (pH 7.4) for 1 min. The brains were then quickly removed
and divided into right and left hemispheres on ice. The cortex,
hippocampus, and olfactory bulb were dissected from the left
hemisphere, snap-frozen in dry ice, and stored at −80 °C for
biochemical analysis. The same treatment was applied to the liver.
The right hemisphere was fixed in 4% paraformaldehyde (PFA) in 0.1
M phosphate buffer (PBS, pH 7.4) for 24 h at 4 °C. The tissue was
then cut into 30 μm thick sections with a freezing sledge microtome
(SM 2000R, Leica) at −20 °C and free-floating sections were
collected in PBS and processed for immunofluorescence.
Plasma Lipid Parameters. Blood was withdrawn intracardially
and EDTA-plasma was prepared within 20 min. Plasma TG (Wiener
lab, Argentine) and total cholesterol (Wiener lab, Argentine)
concentrations were measured enzymatically.
Novel Object Recognition Test. The NOR (Novel Object
Recognition) was performed according to established protocols.43
Briefly, three month old mice, Tg and non Tg subjected to treatment,
were habituated first to an empty open field box of 50 cm × 50 cm ×
30 cm (for 10 min). After 24 h of the habituation session, mice were
exposed to two identical nontoxic “familiar” objects (culture bottles
filled with sand, T25). Between each test, the open field was cleaned
with 70% ethanol to eliminate olfactory signals. After a retention
interval of 4 h, animals were again exposed to the field where two
objects were located, one familiar and one novel (insert cube, red).
The definition of exploring that was used consists of detecting that the
mouse was sniffing, climbing or touching the object or was at a
distance of at least 3 cm from the object, while facing it or facing it.
Each session lasted 10 min, and during this time mice were allowed to
interact freely with the objects and the amount of exploration time of
each object was recorded with the HVS Image software. The objects
were randomized and counterbalanced through the animals. Animals
that spent less than 7 s exploring objects during the 10 min training
session were excluded from the analysis.
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